William Blair Investment Management LLC reduced its stake in shares of Mednax, Inc (NYSE:MD) by 25.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,775,027 shares of the company’s stock after selling 617,627 shares during the period. William Blair Investment Management LLC owned approximately 1.91% of Mednax worth $123,151,000 as of its most recent SEC filing.
Several other institutional investors have also added to or reduced their stakes in the stock. Ladenburg Thalmann Financial Services Inc. boosted its position in Mednax by 5.0% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,604 shares of the company’s stock worth $106,000 after buying an additional 77 shares during the period. Ledyard National Bank raised its position in shares of Mednax by 19.0% in the first quarter. Ledyard National Bank now owns 1,725 shares of the company’s stock worth $120,000 after buying an additional 275 shares during the period. Pacer Advisors Inc. increased its stake in Mednax by 3.2% in the first quarter. Pacer Advisors Inc. now owns 1,795 shares of the company’s stock worth $125,000 after buying an additional 55 shares in the last quarter. Northwestern Mutual Wealth Management Co. increased its stake in Mednax by 870.9% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 2,000 shares of the company’s stock worth $139,000 after buying an additional 1,794 shares in the last quarter. Finally, Morgan Dempsey Capital Management LLC increased its stake in Mednax by 3.6% in the first quarter. Morgan Dempsey Capital Management LLC now owns 2,270 shares of the company’s stock worth $157,000 after buying an additional 78 shares in the last quarter.
Mednax, Inc (MD) opened at 56.59 on Friday. Mednax, Inc has a one year low of $53.80 and a one year high of $76.96. The company has a market cap of $5.23 billion, a P/E ratio of 16.89 and a beta of 0.52. The company’s 50 day moving average price is $55.93 and its 200-day moving average price is $65.04.
Mednax (NYSE:MD) last announced its earnings results on Thursday, May 4th. The company reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.74 by $0.01. The business had revenue of $835.60 million during the quarter, compared to analysts’ expectations of $837.01 million. Mednax had a return on equity of 12.81% and a net margin of 9.54%. The business’s revenue was up 11.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.87 earnings per share. On average, analysts forecast that Mednax, Inc will post $3.61 EPS for the current fiscal year.
MD has been the subject of several recent analyst reports. BidaskClub raised shares of Mednax from a “strong sell” rating to a “sell” rating in a research report on Tuesday. ValuEngine cut Mednax from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Mizuho dropped their price objective on Mednax from $64.00 to $58.00 and set a “neutral” rating on the stock in a research note on Tuesday, May 30th. Stifel Nicolaus lowered their target price on Mednax from $65.00 to $58.00 and set a “hold” rating on the stock in a research note on Thursday, May 25th. Finally, TheStreet cut Mednax from a “b-” rating to a “c+” rating in a research note on Tuesday, May 16th. Two analysts have rated the stock with a sell rating and ten have given a hold rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $66.25.
In related news, CFO Vivian Lopez-Blanco sold 7,778 shares of the stock in a transaction that occurred on Friday, May 5th. The stock was sold at an average price of $55.82, for a total value of $434,167.96. Following the completion of the transaction, the chief financial officer now directly owns 51,319 shares in the company, valued at $2,864,626.58. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Md Pascal J. Goldschmidt sold 1,969 shares of the stock in a transaction that occurred on Wednesday, June 14th. The stock was sold at an average price of $57.57, for a total value of $113,355.33. Following the completion of the transaction, the director now owns 18,072 shares of the company’s stock, valued at $1,040,405.04. The disclosure for this sale can be found here. Insiders sold 33,074 shares of company stock valued at $1,830,508 over the last 90 days. Company insiders own 2.40% of the company’s stock.
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Receive News & Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related companies with MarketBeat.com's FREE daily email newsletter.